Jan 23rd 2013 - Edison Investment Research today published a report on Phylogica entitled "Seeking Phylomer Partnerships". In summary, the report says:
Phylogica’s outlook depends on management’s ability to attract further drug discovery collaborations. Fewer new partnerships have been concluded than expected, but the expansion of Phylogica’s library of Phylomers should aid the formation of new alliances. The potential of therapeutic peptides is gaining appeal as they appear to combine the best characteristics of small molecules and monoclonal antibodies, and Phylomers are a particularly interesting class of peptide due to their diversity and stability. The delays mean we have lowered our valuation to 5.4c (from 5.6c).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »